Guideline-Optimised Treatment in Heart Failure-Do Higher Doses Reduce Systemic Inflammation More Significantly?

Chronic inflammation is a constant phenomenon which accompanies the heart failure pathophysiology. In all phenotypes of heart failure, irrespective of the ejection fraction, there is a permanent low-grade activation and synthesis of proinflammatory cytokines. Many classes of anti-remodelling medication used in the treatment of chronic heart failure have been postulated to have an anti-inflammatory effect.

Metal and Metal Oxide Nanoparticle Incorporation in Polyurethane Foams: A Solution for Future Antimicrobial Materials?

With the technological developments witnessed in recent decades, nanotechnology and nanomaterials have found uses in several common applications and products we encounter daily. On the other hand, polyurethane (PU) foams represent an extremely versatile material, being widely recognized for their extensive application possibilities and possessing a multitude of fundamental attributes that enhance their broad usability across various application fields. By combining the versatility of PU with the antimicrobial properties of nanoparticles, this emerging field holds promise for addressing the urgent need for effective antimicrobial materials in various applications.

Inflammation in Heart Failure-Future Perspectives.

Chronic heart failure is a terminal point of a vast majority of cardiac or extracardiac causes affecting around 1-2% of the global population and more than 10% of the people above the age of 65. Inflammation is persistently associated with chronic diseases, contributing in many cases to the progression of disease. Even in a low inflammatory state, past studies raised the question of whether inflammation is a constant condition, or if it is, rather, triggered in different amounts, according to the phenotype of heart failure.